The finding of a sphingolipid species increased in the plasma of all CF patients vs healthy individuals recalls the recently reported accumulation of ceramides in Cftr-deficent cells and the therapeutic potential of the acid sphingomyelinase inhibitor amitriptilin [39]. The gene discussed is SMPD1; the disease is cystic fibrosis.